Tarsons Products Limited announced the outcome of its Board Meeting held on February 06, 2026. The board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Additionally, the company approved an equity infusion of EUR 3 Million (approximately ₹26.7 crore) in its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to meet operational and financial expenses. This infusion is to be completed in quarterly tranches on or before March 31, 2027. The board also approved the appointment of Mr. Vinesh Mohan Kriplani as an Additional Director (Non-Executive Independent Director) effective February 06, 2026, for a term of five years, subject to shareholder approval. Mr. Kriplani, a Chartered Accountant with over 29 years of experience in taxation and M&A, brings a wealth of expertise from previous roles at EY, KPMG, and PwC. Furthermore, the company accepted the resignation of Mr. Girish Paman Vanvari as an Independent Director, effective February 06, 2026, due to personal commitments. Consequently, the board committees, including the Audit Committee, Nomination and Remuneration Committee, and Risk Management Committee, have been reconstituted to reflect these changes.
